Cargando…

Combination of Bone-Modifying Agents with Immunotarget Therapy for Hepatocellular Carcinoma with Bone Metastases

Due to limited investigations about efficacy of tyrosine kinase inhibitors (TKIs) plus immune-checkpoint inhibitors (ICIs) versus TKIs alone, and effects of durations of bone modifying agents (BMAs) on the survival of patients with hepatocellular carcinoma (HCC) and bone metastases (BoM), we aim to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhaoyu, Shen, Zhilong, Wang, Xiang, Wang, Pengru, Zhu, Xiaofei, Fan, Jiefu, Li, Bo, Xu, Wei, Xiao, Jianru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738198/ https://www.ncbi.nlm.nih.gov/pubmed/36498476 http://dx.doi.org/10.3390/jcm11236901

Ejemplares similares

Immunotargeting of collagenase on thrombus
por: Lu, Yi-ling, et al.
Publicado: (2010)

Immunotargeting in the management of psoriasis
por: Kaffenberger, Benjamin H, et al.
Publicado: (2013)

Immunotargeting of cancer stem cells
por: Kwiatkowska-Borowczyk, Eliza P., et al.
Publicado: (2015)

Prion diseases: immunotargets and therapy
por: Burchell, Jennifer T, et al.
Publicado: (2016)

Immunotargets and Therapy for Prurigo Nodularis
por: Labib, Angelina, et al.
Publicado: (2022)

Immunotargeting of Cancer Stem Cells
por: Köseer, Ayse Sedef, et al.
Publicado: (2023)

Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
por: Birklé, Stéphane, et al.
Publicado: (2013)

Tumor Immunotargeting Using Innovative Radionuclides
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Hairy cell leukemia – immunotargets and therapies
por: Basheer, Faisal, et al.
Publicado: (2014)

Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer
por: Tanaka, Hidekazu, et al.
Publicado: (2020)

Immunotherapy as a Promising Option for the Treatment of Advanced Chordoma: A Systemic Review
por: Wang, Xiang, et al.
Publicado: (2022)

CD146 is a potential immunotarget for neuroblastoma
por: Obu, Satoshi, et al.
Publicado: (2021)

Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents
por: Fukui, Tomoaki, et al.
Publicado: (2023)

Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
por: Ruiz-López, Eduardo, et al.
Publicado: (2022)

Robot and working tube-assisted invasion-controlled surgery for spinal metastases
por: Zhou, Shangbin, et al.
Publicado: (2023)

Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19
por: Mu, Xiuying, et al.
Publicado: (2021)

Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma
por: Chandrasekaran, Deepika, et al.
Publicado: (2019)

Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis
por: Liu, Cun, et al.
Publicado: (2018)

Role of bone-anabolic agents in the treatment of breast cancer bone metastases
por: Suvannasankha, Attaya, et al.
Publicado: (2014)

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
por: Simos, Demetrios, et al.
Publicado: (2013)

Bone metastases as initial presentation of hepatocellular carcinoma
por: Monteserin, Luzdivina, et al.
Publicado: (2017)

Pre-Targeting and Direct Immunotargeting of Liposomal Drug Carriers to Ovarian Carcinoma
por: Lehtinen, Julia, et al.
Publicado: (2012)

Abnormal Innate Immunity in Acute-on-Chronic Liver Failure: Immunotargets for Therapeutics
por: Khanam, Arshi, et al.
Publicado: (2020)

Evaluation of Dimercaptosuccinic Acid-Coated Iron Nanoparticles Immunotargeted to Amyloid Beta as MRI Contrast Agents for the Diagnosis of Alzheimer’s Disease
por: Ulanova, Marina, et al.
Publicado: (2023)

The role of bone‐modifying agents in myeloma bone disease
por: Lu, Huifang, et al.
Publicado: (2021)

Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer
por: D’Oronzo, Stella, et al.
Publicado: (2020)

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
por: Maurer, Margarita, et al.
Publicado: (2012)

Radiographic characteristics of bone metastases from hepatocellular carcinoma
por: Chen, Hai-yan, et al.
Publicado: (2012)

Prognostic factors in hepatocellular carcinoma patients with bone metastases
por: Kim, Sungmin, et al.
Publicado: (2019)

Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials
por: Poon, Michael, et al.
Publicado: (2012)

Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone‐Modifying Agents for Bone Metastases: A Cross‐Sectional Study
por: Kaku, Takumi, et al.
Publicado: (2023)

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis
por: Li, Bo, et al.
Publicado: (2022)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

(68)Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases
por: Guo, Rui, et al.
Publicado: (2021)

In vivo measurement of the association constant of a radio-labelled monoclonal antibody in experimental immunotargeting.
por: Fjeld, J. G., et al.
Publicado: (1992)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
por: Queudeville, Manon, et al.
Publicado: (2017)

Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center
por: Stenehjem, David D., et al.
Publicado: (2019)

NPNT promotes early-stage bone metastases in breast cancer by regulation of the osteogenic niche
por: Wang, Dongsheng, et al.
Publicado: (2018)

Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation
por: He, Jian, et al.
Publicado: (2011)

Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis
por: Omae, Kenji, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_frbbvt6mu8eog47hn9sc4ke143